N-(1-pentyl)-N-methylpropargylamine | 143347-02-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(1-pentyl)-N-methylpropargylamine
• 英文别名: N-(1-Pentyl) N-methylpropargylamine；Methyl-pentyl-prop-2-ynyl-amine; oxalic acid；N-methyl-N-prop-2-ynylpentan-1-amine
• CAS: 143347-02-8
• 化学式: C₉H₁₇N
• 分子量: 139.241
• InChiKey: ZLSSWZIIDZZNDQ-UHFFFAOYSA-N

物化性质

• 沸点：
  182.3±13.0 °C(Predicted)
• 密度：
  0.828±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-氨基戊烷 在 sodium dihydrogenphosphate 作用下， 以 乙醇 、 水 为溶剂， 反应 0.25h， 生成 N-(1-pentyl)-N-methylpropargylamine
  参考文献：
  名称：

  含有可还原、可水解和空间位阻基团的仲胺的还原甲基化

  摘要：

  摘要 脂肪族仲胺，包括那些位阻的仲胺，在温和条件下使用甲醛和亚磷酸钠溶液以高产率进行还原甲基化，而不会还原或水解乙炔基、酯或氰基。

  DOI：

  10.1080/00397910008086975

文献信息

• Fluorogenic/Fluorescent Probes Derivative from Sulfoxanthene, and Use Thereof
  申请人：bioMérieux

  公开号：US20160146814A1

  公开（公告）日：2016-05-26

  The invention relates to fluorescent/fluorogenic probes of formula (I″) or (II″): wherein Z is chosen between: —NH 2 and —OH, or in the fluorescence quencher group consisting of: —NO 2 ; —N═N—R 1 ; R 1 being any organic group that does not obscure the corresponding azo bond; —NHCO-Pept.; Pept. being a peptide residue or any organic group that does not obscure the corresponding amide bond; —O-Glyc.; Glyc. being a oligoglycoside residue that does not obscure the corresponding glycosidic bond; —O—C(O)—R 2 ; —O—P(O)(OR 2 )(OR 2 ′) and —O—S(O) 2 —R 2 ; R 2 and R 2 ′ being independently a hydrogen atom or an organic group that does not obscure the corresponding ester bond; and R a , R b , R c , R d and R e being independently a hydrogen atom or any organic group that does not obscure the corresponding arylether bond so as not to prevent its possible cleavage by a myeloperoxidase activity. It also relates to the use of these fluorescent/fluorogenic probes, for the detection of an enzyme activity, notably in order to identify/discriminate microorganisms in function of their ability to express particular enzyme activities.

  该发明涉及式(I″)或(II″)的荧光/荧光探针： 其中Z在以下选项中选择：—NH2和—OH，或者在荧光猝灭剂基团中选择：—NO2；—N═N—R1；其中R1是任何不遮挡相应偶氮键的有机基团；—NHCO-Pept.；Pept.是肽残基或任何不遮挡相应酰胺键的有机基团；—O-Glyc.；Glyc.是不遮挡相应糖苷键的寡糖苷残基；—O—C(O)—R2；—O—P(O)(OR2)(OR2′)和—O—S(O)2—R2；其中R2和R2′独立地是氢原子或不遮挡相应酯键的有机基团；以及Ra、Rb、Rc、Rd和Re独立地是氢原子或任何不遮挡相应芳基醚键的有机基团，以便不阻止其可能被髓过氧化酶活性水解。 该发明还涉及这些荧光/荧光探针的用途，用于检测酶活性，特别是为了根据微生物表达特定酶活性的能力来识别/区分微生物。
• AMINOQUINOLINE DERIVATIVES AND USES THEREOF
  申请人：THE MCLEAN HOSPITAL CORPORATION

  公开号：US20150023930A1

  公开（公告）日：2015-01-22

  Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.

  本文描述了基于氨基喹啉和氨基蒽醌的混合物，包括含有这种基于氨基喹啉和氨基蒽醌的混合物的制药组合物和药物，以及使用这种化合物诊断和/或治疗感染、神经退行性疾病或障碍、炎症、与炎症相关的疾病和障碍以及可用多巴胺激动剂治疗的疾病或障碍（如不宁腿综合征）的方法。
• FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：Seko Takuya

  公开号：US20080261947A1

  公开（公告）日：2008-10-23

  Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc.), diabetes, shock, head trauma, renal failure, hyperalgesia, etc. Moreover, these compounds are useful as agents against retroviruses (HIV etc.), sensitizers in treating cancer and immunosuppressants.

  式（I）所表示的融合吡嗪衍生物或其药学上可接受的盐（其中每个符号的含义如规范中所定义）。由于抑制了聚(ADP-核糖)聚合酶，式（I）所表示的化合物可用作预防和/或治疗各种缺血性疾病（在大脑、脊髓、心脏、消化道、骨骼肌、视网膜等部位），炎症性疾病（炎症性肠病、多发性硬化症、关节炎等），神经退行性疾病（锥体外系障碍、阿尔茨海默病、肌萎缩症、腰椎管狭窄等），糖尿病、休克、头部创伤、肾功能衰竭、高痛感等。此外，这些化合物还可用作抗逆转录病毒剂（HIV等）、治疗癌症的增敏剂和免疫抑制剂。
• Compositions and Methods for Treatment of Cardiovascular Disorders and Diseases
  申请人：Technion Research & Development Foundation Ltd.

  公开号：EP2433626A1

  公开（公告）日：2012-03-28

  The present invention is directed to the use of S-(-)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for prevention and/or treatment of a cardiovascular disease or disorder.

  本发明涉及 S-(-)-N-丙炔基-1-氨基茚满或其药学上可接受的盐用于制备预防和/或治疗心血管疾病或紊乱的药物组合物。
• Fast dissolving pharmaceutical composition
  申请人：Ferring B.V.

  公开号：US10023335B2

  公开（公告）日：2018-07-17

  The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises levan.

  本发明涉及一种药物组合物，该组合物包含一种携带有药物活性成分的开放式基质网络，其中开放式基质网络包括利凡。